Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 11.11M | $36.0M | 11.35% | -- | 2026-06-30 |
| BlackRock, Inc. | 10.59M | $34.0M | 10.82% | +1.33M | 2026-06-30 |
| ADAR1 Capital Management, LLC | 8.89M | $28.0M | 9.08% | -- | 2026-06-30 |
| Commodore Capital LP | 8.89M | $28.0M | 9.08% | -- | 2026-06-30 |
| RA CAPITAL MANAGEMENT, L.P. | 8.89M | $28.0M | 9.08% | -- | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.14M | $19.0M | 6.28% | +1.94M | 2026-06-30 |
| Paradigm Biocapital Advisors LP | 5.59M | $18.0M | 5.71% | -- | 2026-06-30 |
| Opaleye Management Inc. | 3.86M | $12.0M | 3.95% | +1.93M | 2026-06-30 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.60M | $11.0M | 3.68% | +449.8K | 2026-06-30 |
| Woodline Partners LP | 3.56M | $11.0M | 3.63% | +2.71M | 2026-06-30 |
